Improved survival in patients with recurrent Wilms tumor: The experience of the Seoul National University Children's Hospital

Journal of Korean Medical Science

Volumn 21, Issue 3, 2006, Pages 436-440

  Eun, Sil Park ^a   Hyoung, Jin Kang ^b   Hee, Young Shin ^b,c   Hyo, Seop Ahn ^b  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Children's Hospital   (South Korea)

Author keywords

Nephroblastoma; Recurrence; Salvage Therapy; Stem Cells; Wilms Tumor

Indexed keywords

EID: 33745252811     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.3.436     Document Type: Article

References (17)

1. Grundy P, Breslow N, Green DM, Sharples K, Evans A, D'Angio GJ. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 1989; 7: 638-47.
2. Pinkerton CR, Groot-Loonen JJ, Morris-Jones PH, Pritchard J. Response rates in relapsed Wilms tumor. A need for new effective agents. Cancer 1991; 67: 567-71.
3. Tournade MF, Lemerle J, Brunat-Mentigny M, Bachelot C, Roche H, Taboureau O, Olive D, Lejars O, Boilletot A, Demeocq F. Ifosfamide is an active drug in Wilms tumor: a phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol 1988; 6: 793-6.
4. Pein F, Pinkerton R, Tournade MF, Brunat-Mentigny M, Levitt G, Margueritte G, Rubie H, Sommelet D, Thyss A, Zucker JM. Etoposide in relapsed or refractory Wilms tumor: A phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 1993; 11: 1478-81.
5. Ettinger LJ, Gaynon PS, Krailo MD, Ru N, Baum ES, Siegel SE, Hammond GD. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children's Cancer Group. Cancer 1994; 15: 1297-301.
6. Pein F, Tournade MF, Zucker JM. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor-A phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994; 12: 931-6.
7. Kung FH, Pratt CB, Vega RA, Jaffe N, Strother D, Schwenn M, Nitschke R, Homans AC, Holbrook CT, Golembe B. Etoposide/Ifosfamide combination in the treatment of recurrent malignant solid tumors of childhood: A Pediatric Oncology Group Phase I/II study. Cancer 1993; 71: 1898-903.
8. Garaventa A, Hartmann O, Bernard JL, Zucker JM, Pardo N, Castel V, Dallorso S, Adelbost Z, Ladenstein R, Chauvin F, Phillip T. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 1994; 22: 11-4.
9. Pein F, Michon J, Valteau-Couanet D, Quintana E, Frappaz D, Vannier JP, Philip T, Bergeron C, Baranzelli MC, Thyss A, Stephan JL, Boutard P, Gentet JC, Zucker JM, Tournade MF, Hartmann O. High dose melphalan, etoposide, and carboplatin followed by autologous stem cell rescue in pediatric high risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998; 16: 3295-301.
10. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, Hero B, Selle B, Niemeyer C, Finckenstein FG, Schulz A, Wawer A, Zintl F, Graf N. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant 2002; 30: 893-8.
11. Campbell AD, Cohn SL, Reynolds M, Seshadri R, Morgan E, Geissler G, Rademaker A, Marymount M, Kalapurakal J, Haut PR, Duerst R, Kletzel M. Treatment of relapsed Wilms tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J Clin Oncol 2004; 15: 2885-90.
12. D'Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Feigl P, Goodwin W, Leape LL, Sinks LF, Sutow W, Tefft M, Wolff J. The treatment of Wilms' tumor: Result of National Wilms' Tumor Study. Cancer 1976; 38: 633-46.
13. Tannous R, Giller R, Holmes E. Intensive therapy for high-risk relapsed Wilms' tumor. A CCG-4921/POG-9445 study report. Proc Am Soc Clin Oncol 2000; 19 (Abstr 2315).
14. Suh WS, Kang IJ, Koo HH, Kook H, Kim SK, Kim HK, Kim HM, Kim HS, Park KD, Park KB, Park SK, Park JS, Park JE, Park HJ, Seo JJ, Sung KW, Shin HY, Ahn HS, Yang CH, Yoo KH, Yoo ES, Lyu CJ, Lee KC, Lee KS, Lee SY, Lee YH, Lim YT, Jang PS, Chung NG, Jeong DC, Jung HL, Cho DW, Cho B, Choi YM, Hah JO, Hwang PH, Hwang TJ. Epidemiology and clinical outcomes of childhood Wilms tumor in Korea. Korea J Pediatr Hematol-Oncol 2004; 11: 164-70.
15. Choi YD, Han SW, Choi SK, Ko WJ, Lee JS, Lee SJ, Han SJ, Hwang EH, Yu CJ, Kim BS. Prognostic factors and survival rates of preoperative and recurred cases chemotherapy in Wilms' tumor. Korean J Urol 2000; 41: 741-6.
16. Kung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, Krischer JP, Murphy SB, Pratt CB, Toledano S, Wiley JM, Yu AL. Ifosfamide, carboplatin, etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 1995; 17: 265-9.
17. Abu-Ghosh AM, Krailo MD, Glodman SC, Slack RS, Davenport V, Morris E, Laver JH, Reaman GH, Cairo MS. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann oncol 2002; 13: 460-9.